Yang Jian, Craddock Lauren, Hong Sharon, Liu Zhi-Mei
Department of Physiology, University of South Alabama College of Medicine, Mobile, Alabama 36688, USA.
J Cell Biochem. 2009 Feb 15;106(3):414-26. doi: 10.1002/jcb.22024.
AMP-activated protein kinase (AMPK) is an intracellular fuel sensor that plays a key role in regulating fatty acid synthesis in liver. Sterol regulatory element-binding protein (SREBP)-1c is a master regulator of hepatic lipogenic gene expression. It has long been documented that AMPK activation suppresses hepatic SREBP-1 mRNA and nuclear SREBP-1 protein. But the mechanism remains undefined. In this study we investigated the molecular mechanisms by which AMPK downregulates hepatic SREBP-1c mRNA using a novel model cell line McA-RH7777. We found that AMPK is robustly activated in rat hepatoma McA-RH7777 cells treated with two widely used AMPK activators, AICAR and metformin, and AMPK activation sharply suppresses SREBP-1c mRNA and nuclear SREBP-1c protein, but not SREBP-1a mRNA derived from the same gene. These inhibitory effects are reversed by the AMPK inhibitor Compound C or 8-BrAMP, demonstrating the requirement of AMPK in the suppression of SREBP-1c mRNA and nuclear SREBP-1c protein by AICAR and metformin. AMPK does not enhance SREBP-1c mRNA degradation in the presence of the general transcription inhibitor actinomycin D; instead it inhibits SREBP-1c promoter activity in a luciferase reporter assay. AMPK-mediated inhibition of SREBP-1c promoter activity can also be abrogated by the AMPK inhibitor Compound C. Furthermore AMPK activation significantly attenuates the synthetic liver X receptor (LXR) ligand T0901317-induced SREBP-1c promoter activity. AMPK also inhibits cleavage of LXR ligand-induced SREBP-1c precursor. We conclude that AMPK suppresses hepatic SREBP-1c mRNA expression by inhibiting LXR-dependent SREBP-1c transcription via inhibition of endogenous LXR ligand production and by inhibiting SREBP-1c processing in McA-RH7777 cells.
AMP激活的蛋白激酶(AMPK)是一种细胞内的能量传感器,在调节肝脏脂肪酸合成中起关键作用。固醇调节元件结合蛋白(SREBP)-1c是肝脏脂肪生成基因表达的主要调节因子。长期以来有文献记载,AMPK激活可抑制肝脏SREBP-1 mRNA和核SREBP-1蛋白。但具体机制仍不明确。在本研究中,我们使用新型模型细胞系McA-RH7777研究了AMPK下调肝脏SREBP-1c mRNA的分子机制。我们发现,在用两种广泛使用的AMPK激活剂AICAR和二甲双胍处理的大鼠肝癌McA-RH7777细胞中,AMPK被强烈激活,且AMPK激活会显著抑制SREBP-1c mRNA和核SREBP-1c蛋白,但不影响源自同一基因的SREBP-1a mRNA。这些抑制作用可被AMPK抑制剂Compound C或8-BrAMP逆转,表明AMPK在AICAR和二甲双胍抑制SREBP-1c mRNA和核SREBP-1c蛋白过程中是必需的。在存在通用转录抑制剂放线菌素D的情况下,AMPK不会增强SREBP-1c mRNA的降解;相反,在荧光素酶报告基因检测中它会抑制SREBP-1c启动子活性。AMPK抑制剂Compound C也可消除AMPK介导的对SREBP-1c启动子活性的抑制作用。此外,AMPK激活可显著减弱合成型肝脏X受体(LXR)配体T0901317诱导的SREBP-1c启动子活性。AMPK还可抑制LXR配体诱导的SREBP-1c前体的切割。我们得出结论,在McA-RH7777细胞中,AMPK通过抑制内源性LXR配体产生从而抑制LXR依赖的SREBP-1c转录,并通过抑制SREBP-1c加工过程来抑制肝脏SREBP-1c mRNA表达。